Imricor Medical Systems (IMR) Investor presentation summary

Strategic vision and market opportunity

• Aims to bring MRI-guided interventional cardiac procedures (iCMR) to every cardiac center globally, leveraging 20 years of ecosystem development in MRI-compatible devices and software.

• Holds over 90 patents and maintains deep integration with major MRI vendors, creating a defensible technology moat.

• Only provider of a commercially viable MRI-compatible cardiac ablation system, targeting a cardiac ablation market projected to grow at ~15% CAGR to $60bn by 2035.

• Platform compatibility across major MRI vendors, with expansion into pediatric applications underway.

Equity raising and use of proceeds

• Launching an A$60 million institutional placement at A$1.85 per share, a 6.3% discount to last close, representing 10.1% of existing shares.

• Proceeds allocated to sales and marketing (31%), R&D (24%), clinical trials and regulatory compliance (27%), and working capital (18%).

• Post-raise, pro-forma cash balance expected to be US$74m/A$108m, supporting a cash runway into 2028.

• Funds will drive U.S. and Middle East expansion, regulatory approvals, clinical trials, and product portfolio growth.

Product and business model highlights

• MRI-compatible ablation and diagnostic catheters, mapping systems, and capital equipment enable real-time, radiation-free cardiac procedures.

• Business model combines capital sales with high-margin recurring revenue from consumables and annual licenses.

• Each new lab installation generates US$500k–$700k in capital revenue and up to $3m in recurring revenue per hospital annually.

• Demonstrated value for all stakeholders: improved patient outcomes, faster procedures, lower costs, and higher hospital throughput.